1.Comparison of the effect of laparoscopic cholecystectomy with radical cholecystectomy on patients with early gallbladder carcinoma
Qiang XU ; Gang SU ; Baoding LI ; Jianghe WU
Clinical Medicine of China 2010;26(9):972-974
Objective To compare the efficiency of laparoscopic cholecystectomy (LC) and radical cholecystectomy (RC) in the patients with early gallbladder carcinoma. Methods From January 2001 to December 2008, 63 patients who had underwent LC(28 cases) or RC(35 cases) were analyzed retrospectively. The survival and recurrence rate after operation and complication were compared. Results After treatment, the complication in the LC group was less than that in the RC group (7. 1% vs. 48. 6%, χ2 = 12. 675 ,P <0.01). In the RC group,the 1,3,5 year overall cumulative survival rate of Nevein phase Ⅰ were all 100%, and 76. 2%, 42. 9%, and 23. 8% respectively in the phase Ⅱ. The overall cumulative survival rate of LC cases were 81.8%, 54. 5%,27.3% in phase Ⅰ and 17.6% ,5.9% ,0.0% in phase Ⅱ, respectively. The survival curves between the two groups were significantly diffierent(phase Ⅰ χ2 =20.74,P<0.001; phase Ⅱ χ2 = 11.35,P<0.001) and the survival rate in the RC group was higher than that in the LC group. The 1,3,5 year cumulative recurrence rates in the RC were 20.0%, 48. 6%, 68. 6%, respectively, which is significantly lower than those in the LC group (60.7%,85.7% and92.9%, respectively)(χ2 =10.30,P=0.0013).Conclusions RC is one of the first choices for early gallbladder carcinoma treatment, and will decrease the recurrence rate and improve the long-term life quality.
2.Targeting castration-resistant prostate cancer with a novel ROR
Jianwei ZHENG ; Junfeng WANG ; Qian WANG ; Hongye ZOU ; Hong WANG ; Zhenhua ZHANG ; Jianghe CHEN ; Qianqian WANG ; Panxia WANG ; Yueshan ZHAO ; Jing LU ; Xiaolei ZHANG ; Songtao XIANG ; Haibin WANG ; Jinping LEI ; Hong-Wu CHEN ; Peiqing LIU ; Yonghong LIU ; Fanghai HAN ; Junjian WANG
Acta Pharmaceutica Sinica B 2020;10(12):2313-2322
Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor ROR